Steatohepatitis: Difference between revisions
| Line 13: | Line 13: | ||
==Prognosis== | ==Prognosis== | ||
A retrospective [[cohort study]] concluded that "liver failure is the main cause of morbidity | A retrospective [[cohort study]] concluded that "liver failure is the main cause of morbidity and mortality in NASH-associated cirrhosis. The prognosis is either similar or less severe than HCV-cirrhosis."<ref name="pmid12883486">{{cite journal |author=Hui JM, Kench JG, Chitturi S, ''et al'' |title=Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C |journal=Hepatology |volume=38 |issue=2 |pages=420–7 |year=2003 |pmid=12883486 |doi=10.1053/jhep.2003.50320}}</ref> | ||
and mortality in NASH-associated cirrhosis. The prognosis is either similar or less severe | |||
than HCV-cirrhosis."<ref name="pmid12883486">{{cite journal |author=Hui JM, Kench JG, Chitturi S, ''et al'' |title=Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C |journal=Hepatology |volume=38 |issue=2 |pages=420–7 |year=2003 |pmid=12883486 |doi=10.1053/jhep.2003.50320}}</ref> | |||
==References== | ==References== | ||
Revision as of 16:43, 5 March 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Template:Search infobox Steatohepatitis is a type of liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver ("steato", meaning fat, "hepatitis", meaning inflammation of the liver). Classically seen in alcoholics, steatohepatitis also is frequently found in people with diabetes and obesity. When not associated with excessive alcohol intake, it's referred to as "non-alcoholic steatohepatitis", or NASH. Steatohepatitis of either etiology may progress to cirrhosis, and NASH is now believed to be a frequent cause of unexplained cirrhosis (at least in Western societies).
Treatment
Recent studies suggest that diet, exercise, and especially antiglycemic drugs may alter the course of the disease. A randomized controlled trial found that "pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis".[1]
Prognosis
A retrospective cohort study concluded that "liver failure is the main cause of morbidity and mortality in NASH-associated cirrhosis. The prognosis is either similar or less severe than HCV-cirrhosis."[2]
References
- ↑ Belfort R, Harrison SA, Brown K; et al. (2006). "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis". N. Engl. J. Med. 355 (22): 2297–307. doi:10.1056/NEJMoa060326. PMID 17135584.
- ↑ Hui JM, Kench JG, Chitturi S; et al. (2003). "Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C". Hepatology. 38 (2): 420–7. doi:10.1053/jhep.2003.50320. PMID 12883486.
See also
- steatosis hepatis
- Hepatitis CLong-Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis C
Template:Skin and subcutaneous tissue symptoms and signs Template:Nervous and musculoskeletal system symptoms and signs Template:Urinary system symptoms and signs Template:Cognition, perception, emotional state and behaviour symptoms and signs Template:Speech and voice symptoms and signs Template:General symptoms and signs